Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Medroxyprogesterone acetate and lipid metabolic changes.

A T Teichmann, H E Wander, P Cremer

Arzneimittel-Forschung

|May 1, 1987

Summary

Medroxyprogesterone acetate (MPA) at higher doses significantly alters lipid profiles, decreasing HDL cholesterol and increasing LDL cholesterol. Lower doses showed no significant lipid changes in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Linking sap flow and tree water deficit in an unmanaged, mixed beech forest during the summer drought 2022.

Plant biology (Stuttgart, Germany)·2024

Same author

Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020

Same author

Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016.

The Journal of hospital infection·2018

Same author

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Same author

[Evaluation of the infrastructure for clinical surgical studies in Germany : A nationwide survey of the surgical study network CHIR-Net].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2018

Same author

[What is new in symptomatic MS treatment: Part 3-bladder dysfunction].

Der Nervenarzt·2017

Area of Science:

Endocrinology
Cardiovascular Research
Pharmacology

Background:

Medroxyprogesterone acetate (MPA) is used to treat various gynecological and oncological conditions.
Understanding MPA's impact on lipid metabolism is crucial for assessing potential cardiovascular risks.
Previous studies on MPA's effects on lipids have yielded varied results, necessitating further investigation.

Purpose of the Study:

To investigate the effects of oral medroxyprogesterone acetate (MPA) on lipid and lipoprotein metabolism.
To determine dose-dependent changes in lipid profiles associated with MPA treatment.
To evaluate the potential atherogenic implications of MPA-induced lipid alterations.

Main Methods:

Four patient groups received varying daily oral doses of MPA for endometriosis, endometrial carcinoma, or breast cancer.

Related Experiment Videos

Lipid parameters including cholesterol, triglycerides, lipoproteins (alpha and beta), and apolipoproteins (A1 and B) were measured.

Quantitative electrophoresis, precipitation, and kinetic rate nephelometry were employed for analyses.

Main Results:

Low-dose MPA (50 mg/day) did not alter lipid or lipoprotein parameters.
Higher MPA doses (200 mg/day and above) significantly decreased alpha-lipoprotein, HDL-cholesterol, and apolipoprotein A1 levels.
Significant increases in beta-lipoprotein, LDL-cholesterol, and apolipoprotein B concentrations were observed with higher MPA doses.

Conclusions:

Oral MPA at doses of 200 mg/day or higher induces unfavorable changes in lipid profiles.
These changes, characterized by reduced HDL and increased LDL, may carry atherogenic risks.
Further research is warranted to fully elucidate the long-term cardiovascular implications of MPA therapy.